期刊
THERANOSTICS
卷 11, 期 13, 页码 6592-6606出版社
IVYSPRING INT PUBL
DOI: 10.7150/thno.59816
关键词
tumor suppressor gene; targeted therapy; drug resistance
资金
- National Natural Science Foundation of China [81972778, 31800723, 81672309, 31701188, 81774376]
- Guangzhou Research Project of Science and Technology for Citizen Health [201803010124]
- Fundamental Research Funds for the Central Universities [21619101, 21618326]
- Guangdong Natural Science Foundation [2021A1515010461]
- Science and Technology Program of Guangdong [2017B020227001]
In this study, MYOCD was identified as a clinically relevant tumor suppressor gene in lung cancer patients, showing a potent inhibitory effect on lung cancer stem cells. NSCLC cells deficient of MYOCD were found to be particularly sensitive to TGFBR kinase inhibitor, and a synergistic effect was observed when combining TGFBRi with stemness inhibitor to treat MYOCD deficient lung cancers.
Purpose: Clinical success of cancer therapy is severely limited by drug resistance, attributed in large part to the loss of function of tumor suppressor genes (TSGs). Developing effective strategies to treat those tumors is challenging, but urgently needed in clinic. Experimental Design: MYOCD is a clinically relevant TSG in lung cancer patients. Our in vitro and in vivo data confirm its tumor suppressive function. Further analysis reveals that MYOCD potently inhibits stemness of lung cancer stem cells. Mechanistically, MYOCD localizes to TGFBR2 promoter region and thereby recruits PRMT5/MEP50 complex to epigenetically silence its transcription. Conclusions: NSCLC cells deficient of MYOCD are particularly sensitive to TGFBR kinase inhibitor (TGFBRi). TGFBRi and stemness inhibitor synergize with existing drugs to treat MYOCD deficient lung cancers. Our current work shows that loss of function of MYOCD creates Achilles' heels in lung cancer cells, which might be exploited in clinic.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据